title: Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients.
abstract: BACKGROUND
  Survivin is an inhibitor of apoptosis and a regulator of mitotic progression. TP53 protein is a negative transcriptional regulator of survivin. The aim of our study was to evaluate the clinical significance of survivin expression in advanced stages ovarian cancer with respect to the TP53 status.
  
  
  METHODS
  Survivin and TP53 expression was evaluated immunohistochemically in 435 archival samples of ovarian carcinomas (244 patients were treated with platinum/cyclophosphamide-PC/PAC; 191-with taxane-platinum (TP) agents). Univariate and multivariate statistical analyses were performed in patients groups divided according to the administered chemotherapeutic regimen, and in subgroups with and without TP53 accumulation (TP53+ and TP53-, respectively).
  
  
  RESULTS
  Nuclear and cytoplasmic survivin expression was observed in 92% and 74% of the carcinomas, respectively. In patients treated with TP, high nuclear survivin expression decreased the risk of disease recurrence and death, and increased the probability of high platinum sensitivity (p < 0.01), but only in the TP53(+) group, and not in the TP53(-) group.
  
  
  CONCLUSIONS
  It appears that TP53 status determines the clinical importance of nuclear survivin expression in taxane-platinum treated ovarian cancer patients.
authors.affiliation: Department of Molecular Pathology, The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland. jkupry@coi.waw.pl.
authors.forename: Anna
authors.initials: A
authors.lastname: Felisiak-Golabek
authors.forename: Alina
authors.initials: A
authors.lastname: Rembiszewska
authors.forename: Iwona K
authors.initials: IK
authors.lastname: Rzepecka
authors.forename: Lukasz
authors.initials: L
authors.lastname: Szafron
authors.forename: Radoslaw
authors.initials: R
authors.lastname: Madry
authors.forename: Magdalena
authors.initials: M
authors.lastname: Murawska
authors.forename: Tomasz
authors.initials: T
authors.lastname: Napiorkowski
authors.forename: Piotr
authors.initials: P
authors.lastname: Sobiczewski
authors.forename: Beata
authors.initials: B
authors.lastname: Osuch
authors.forename: Jolanta
authors.initials: J
authors.lastname: Kupryjanczyk
references.citation: Ann Oncol. 2004 Nov;15(11):1654-60
references.pmid: 15520067
references.citation: Eur J Surg Oncol. 2003 May;29(4):379-82
references.pmid: 12711293
references.citation: Br J Cancer. 2004 Nov 29;91(11):1916-23
references.pmid: 15545967
references.citation: J Cell Sci. 2002 Feb 1;115(Pt 3):575-85
references.pmid: 11861764
references.citation: Mol Pharmacol. 1998 May;53(5):819-26
references.pmid: 9584207
references.citation: Br J Cancer. 2003 Apr 7;88(7):1077-83
references.pmid: 12671708
references.citation: Br J Cancer. 1998 Aug;78(3):375-81
references.pmid: 9703286
references.citation: Gynecol Oncol. 1994 Dec;55(3 Pt 2):S143-50
references.pmid: 7835799
references.citation: Int J Gastrointest Cancer. 2002;32(2-3):73-81
references.pmid: 12794243
references.citation: J Clin Oncol. 2000 Dec 1;18(23):3936-45
references.pmid: 11099323
references.citation: Cancer. 1981 Jan 1;47(1):207-14
references.pmid: 7459811
references.citation: Biochem Pharmacol. 1999 Jun 1;57(11):1215-21
references.pmid: 10230764
references.citation: Endocr Relat Cancer. 2009 Sep;16(3):1005-16
references.pmid: 19458022
references.citation: Cancer Res. 2003 Jun 1;63(11):2794-801
references.pmid: 12782584
references.citation: Expert Opin Pharmacother. 2001 Aug;2(8):1299-306
references.pmid: 11584998
references.citation: Cancer Treat Rev. 2006 May;32(3):166-79
references.pmid: 16527420
references.citation: Br J Cancer. 2005 Jan 31;92(2):271-7
references.pmid: 15655541
references.citation: Nature. 1998 Dec 10;396(6711):580-4
references.pmid: 9859993
references.citation: Cancer Lett. 2007 Apr 28;249(1):49-60
references.pmid: 17275177
references.citation: Cancer Treat Rev. 2009 Nov;35(7):553-62
references.pmid: 19559538
references.citation: Nat Med. 1996 Jan;2(1):72-9
references.pmid: 8564846
references.citation: J Cell Biol. 2000 Dec 25;151(7):1575-82
references.pmid: 11134084
references.citation: Mol Cancer Ther. 2006 May;5(5):1087-98
references.pmid: 16731740
references.citation: Am J Obstet Gynecol. 1975 Mar 15;121(6):795-807
references.pmid: 1092171
references.citation: Gynecol Oncol. 2006 Jan;100(1):5-7
references.pmid: 16169062
references.citation: Cancer Res. 1998 May 1;58(9):1808-12
references.pmid: 9581817
references.citation: Cell Mol Life Sci. 2002 Aug;59(8):1406-12
references.pmid: 12363043
references.citation: Mod Pathol. 2003 Jun;16(6):574-83
references.pmid: 12808063
references.citation: Am J Pathol. 2004 Feb;164(2):501-10
references.pmid: 14742256
references.citation: Pathol Res Pract. 2008;204(4):241-9
references.pmid: 18171606
references.citation: Br J Cancer. 2004 Aug 2;91(3):537-40
references.pmid: 15266313
references.citation: BMC Cancer. 2008 Jan 29;8:27
references.pmid: 18230133
references.citation: Eur J Cancer. 2007 Jan;43(1):194-201
references.pmid: 17046239
references.citation: Ann Hum Genet. 2006 Sep;70(Pt 5):594-604
references.pmid: 16907706
references.citation: Gynecol Oncol. 2003 Sep;90(3 Pt 2):S8-15
references.pmid: 13129490
references.citation: Cancer Res. 2002 May 1;62(9):2462-7
references.pmid: 11980633
references.citation: Br J Cancer. 2003 Jan 13;88(1):115-9
references.pmid: 12556969
references.citation: Gynecol Oncol. 2009 Jan;112(1):179-84
references.pmid: 18937971
references.citation: Anticancer Res. 2006 Jan-Feb;26(1B):687-93
references.pmid: 16739339
references.citation: Cancer Lett. 2006 Sep 28;241(2):289-300
references.pmid: 16459017
references.citation: N Engl J Med. 1996 Jan 4;334(1):1-6
references.pmid: 7494563
references.citation: FASEB J. 2007 Jan;21(1):207-16
references.pmid: 17099069
references.citation: J Cell Sci. 2003 Jul 15;116(Pt 14):2987-98
references.pmid: 12783991
references.citation: Int J Cancer. 2005 Apr 20;114(4):509-12
references.pmid: 15578717
references.citation: Nat Med. 1997 Aug;3(8):917-21
references.pmid: 9256286
references.citation: Cancer Res. 2008 Jul 1;68(13):5159-66
references.pmid: 18593915
references.citation: Oncogene. 2002 Apr 18;21(17):2613-22
references.pmid: 11965534
references.citation: Br J Cancer. 2003 Mar 24;88(6):848-54
references.pmid: 12644821
references.citation: Int J Cancer. 2001 Jun 1;92(5):738-47
references.pmid: 11340581
references.citation: Am J Pathol. 1998 Jan;152(1):43-9
references.pmid: 9422522
references.citation: Oncogene. 2007 Jan 11;26(2):290-7
references.pmid: 16847456
references.citation: Cancer Res. 2004 Apr 1;64(7):2502-8
references.pmid: 15059905
references.citation: J Biol Chem. 2002 Feb 1;277(5):3247-57
references.pmid: 11714700
references.citation: Chromosoma. 2004 Nov;113(5):211-22
references.pmid: 15351889
references.citation: Cancer Res. 2004 Dec 1;64(23):8708-14
references.pmid: 15574781